Original Article



A high prevalence of antibiotic use at two large teaching hospitals in Addis Ababa, Ethiopia: a point prevalence survey

Kassa Haile Merga MD, MPH¹ , Edlawit Mesfin Getachew MD¹, Ayako Wendy Fujita MD², Mahlet Abayneh MD³, Jesse T. Jacob MD, MSc², Solomon Ali PHD³, Hayat Oumer Melesse MD⁴, Ahmed Babiker MBBS, MSc², Liya Sisay Getachew MD¹, Tsegaye Hailu MSc¹, Jemal Mohammed MSc¹, Bethelhem Solomon MD¹, Paulina A. Rebolledo MD, MSc², Alemseged Abdissa PHD¹ and Russell R. Kempker MD, MSc², ¹ ¹Armauer Hansen Research Institute, Addis Ababa, Ethiopia, ²Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, USA, ³St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia and ⁴ALERT Center, Addis Ababa, Ethiopia

Abstract

Objective: Antimicrobial resistance (AMR) renders many bacterial infections untreatable and results in substantial morbidity and mortality worldwide. Understanding antibiotic use in clinical settings including hospitals is critical to optimize antibiotic use and prevent resistance.

Design: Hospital antibiotic point prevalence survey (PPS).

Methods: The study was conducted in two large, teaching hospitals in Addis Ababa, Ethiopia. We performed two survey rounds in December 2021 and January 2022 through real-time chart review using the World Health Organization PPS methodology. Data were collected using a web-based database, and descriptive statistics were performed to analyze antibiotic use by various characteristics.

Results: Among 1020 hospitalized patients, 318 (32%) were \leq 14 years and 370 (36%) had surgery during the current hospitalization. A total of 662 (65%) were receiving an antibiotic on the day of survey and 346 (39%) were receiving \geq 2 antibiotics. A community-acquired infection (43%) was the most common indication for an antibiotic followed by surgical prophylaxis (27%) and hospital-acquired infection (23%). Antibiotic use was highest among those \leq 24 months in age and among patients in trauma, surgical, and pediatric wards. Cephalosporin (42%) and penicillin (16%) antibiotics were the most frequently prescribed classes. Only 11% of patients on antibiotics had samples collected for microbiological testing; hence, almost all antibiotic therapy was empiric.

Conclusions: Despite global and national efforts to improve antimicrobial stewardship, antibiotic use remains high in urban teaching hospitals in Ethiopia. Implementation of antimicrobial stewardship activities and microbiology utilization are needed to guide antimicrobial selection and curtail antibiotic overuse.

(Received 31 May 2024; accepted 21 August 2024)

Introduction

Antimicrobial resistance (AMR) continues to be a serious threat to global health, and the crisis is predicted to worsen unless major changes are made to curtail antibiotic overuse and misuse. The emergence of AMR renders many common bacterial infections untreatable and results in substantial morbidity and mortality worldwide.¹ An estimated 4.9 million deaths are associated with bacterial AMR infections worldwide per year, including 1 million in the African continent.^{2–4} The misuse of antimicrobials including inappropriate, unregulated, and overuse of antimicrobials contributes to the development of AMR.^{1,4} Alarmingly, a spatial modeling study found an increase of 46% in antibiotic

Cite this article: Merga KH, Getachew EM, Fujita AW, *et al.* A high prevalence of antibiotic use at two large teaching hospitals in Addis Ababa, Ethiopia: a point prevalence survey. *Antimicrob Steward Healthc Epidemiol* 2024. doi: 10.1017/ash.2024.432

consumption among humans globally between 2000 and 2018; however, data on antibiotic use in many regions including Africa are scarce.⁵ Understanding current antibiotic use in various geographical and healthcare settings is critical in developing and optimizing antimicrobial stewardship programs, which are important to guide appropriate antibiotic use and prevent the development of AMR.

In 2015, the World Health Organization (WHO) adopted a global action plan on AMR, with the optimal use of antimicrobials being one of five key objectives.⁶ The WHO point prevalence survey (PPS) methodology was developed to harmonize data collection on antimicrobial use, for local, national, and international comparision.⁷ The first global PPS of antimicrobial consumption was conducted in 2015⁸ and found that the overall prevalence of antimicrobial use in hospital settings was 34%. However, there were variations across regions, ranging from 27% in Eastern Europe to 50% in Africa.^{9,10} Most Sub-Saharan African

Corresponding author: Kassa Haile Merga; Email: kassa.haile@ahri.gov.et

[©] The Author(s), 2024. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.

nations report high rates of antimicrobial usage with prevalence use rates ranging from 52-88%.¹¹⁻¹⁴

The few studies on antibiotic use conducted in Ethiopia to date have indicated high rates of administration.^{15–19} Recognizing the escalating threat of AMR, the Ethiopian government has formulated a comprehensive and multisectoral approach to effectively contain the spread of AMR.²⁰ Additional data on the current landscape of hospital-based antibiotic prescribing practices will guide the implementation of future stewardship activities and promote effective antibiotic use in tertiary care settings. The aim of our study was to estimate the contemporary prevalence of antibiotic use at two large teaching hospitals in Addis Ababa, Ethiopia.

Methods

Study design and setting

We conducted a cross-sectional, PPS of antibiotic use at two large, referral hospitals located in Addis Ababa, Ethiopia, including the All-Africa Leprosy, Tuberculosis and Rehabilitation and Training Center (ALERT) Hospital and Saint Paul's Hospital Millennium Medical College (SPHMMC). ALERT Hospital is a teaching hospital with 377 beds that includes 35 intensive care unit (ICU) beds as well as adult, pediatric, surgical, obstetrics and gynecology (OB/GYN), and trauma wards with approximately 40–50 total hospital admissions per day. SPHMMC is a 700-bed hospital with adult wards (medical, surgical, emergency, ICU), pediatric wards (medical, surgical, emergency, ICU), neonatal ICU (NICU), and OB/GYN wards. Both hospitals have an onsite microbiology laboratory and pharmacy but neither has an established antimicrobial stewardship program.

Study criteria

We aimed to survey all hospitalized patients, encompassing neonates, children, adolescents, and adults, including pregnant women, during each PPS administration. All patients present in the survey ward at 8:00 a.m. on the day of data collection were eligible for inclusion. Neonates born before 8:00 a.m. on the survey day were included and considered separately from their mothers.

Exclusion criteria comprised patients seen in outpatient departments, emergency departments, same-day surgery appointments, or outpatient dialysis units. Additionally, those discharged before 8:00 a.m. but remaining in the hospital were excluded. Neonates of uncertain viability and nonviable neonates were excluded.

Data collection

We adapted and designed our PPS questionnaire based on WHO guidance.²¹ patient data, including demographics, clinical variables, and antibiotic use details such as antibiotic type, infection source (hospital vs community-acquired), prophylactic antibiotic use, infectious syndrome types treated, and available microbiological data. Definitions for these variables, based on WHO PPS methodology, are detailed in the Supplemental Material. (Supplemental Tables 1 and 2).

Two teams of data collectors comprised of medical practitioners received training on all study protocols and procedures related to conducting the survey and data collection.⁷ We conducted a pilot PPS of 10 patients at both hospitals a month prior to data collection and made minor changes to enhance and facilitate accurate data collection and interpretability. We conducted two rounds of the

antibiotic PPS in December 2021 and January 2022. Each round of data collection spanned five consecutive working days, with data collected sequentially across the wards. Data collection for each patient and ward was completed within a single day. Data collectors reviewed patient charts and laboratory records to collect information and de-identified data into an online REDCap database using an electronic tablet.²²

Ethical consideration

Ethical clearance and waiver of informed consent were obtained from the ALERT-AHRI ethical review committee and institutional review board (IRB) of SPHMMC. A letter of support to conduct the survey was obtained from ALERT hospital and SPHMMC. An IRB exemption was provided by the Emory University IRB.

Data management and analysis

We defined antibiotic use as a patient having an active prescription for an antibiotic on the day of survey. Indications for antibiotic use and infectious syndrome were defined using similar methodology as described in the WHO PPS guide.²³ We exported data into STATA statistical software Version 17, STATA CORP MP for statistical analysis. We utilized descriptive statistics to assess the prevalence of antibiotic use and various patient and healthcare characteristics.

Results

Patient demographics

A total of 1,020 patients from both hospitals were included in the study. Among them, 514 (50%) were male, and 318 (31%) were \leq 14 years old. The rate of known human immunodeficiency virus infection was low at 3%. Patients from various ward types were included as outlined in Table 1 and included 21% admitted to a surgical ward, 19% to a gynecology ward, and 15% to a NICU. The median hospital stay at the time of survey was 6 days (interquartile range 2–15) and a similar prevalence of patients had been either transferred from another hospital (12%) or had been hospitalized within the previous 90 days (11%). Notably, 343 (34%) of the participants had undergone a major surgery since their admission to the hospital.

Prevalence of antibiotic use

A total of 662 (65%) patients were receiving ≥ 1 antibiotic at the time of survey. Antibiotic use was similar during the two different time periods and was higher at ALERT versus SPHMMC hospital. A high proportion of children in both the 0–28 days (76%) and 1-24 months (83%) age categories were receiving antibiotics. Antibiotic use was highest in trauma (84%) and surgical (78%) wards along with various pediatric wards including general pediatric (78%), pediatric ICU (78%), and NICU (74%) wards. Among the 271 patients who had major surgery, 79% were receiving antibiotics. Antibiotic use was also high among patients with a urinary catheter (82%). Antibiotic use by included characteristics is shown in Table 1.

Antibiotic use characteristics

Among the 662 patients receiving antibiotics at the time of the PPS, the majority of patients were receiving ≥ 2 antibiotics. The most frequent indications for antibiotic use were community-acquired infection (43%) and surgical prophylaxis (27%). While the reason

 Table 1.
 Characteristics of hospitalized patients included in antibiotic use point prevalence survey by antibiotic use in Addis Ababa, Ethiopia, December 2020–January 2021 (n = 1020)

	Total number of participants	Patients on Antibiot
Characteristics	$N = 1020 (\%)^{a}$	$N = 662 (\%)^{b}$
Gender (<i>N</i> = 1019, missing = 1)		
Male	514 (50.4%)	359 (69.8%)
Female	505 (49.5%)	302 (59.8 %)
Enrollment Period		
Round 1	506	331 (65.9 %)
Round 2	514	331 (63.9%)
Study Hospital		
Hospital 1 SPHMMC	472 (46.3%)	255 (41%)
Hospital 2ALERT	548 (53.7%)	407 (61.5%)
Age Categories (N = 1005, missing = 15)		
0-28 days	144 (14.3%)	108 (76%)
1–24 months	76 (7.6 %)	63 (82.9%)
2–14 years	98 (9.8%)	60 (61.2%)
>14 years	687 (66.1%)	421 (61.3%)
Hospital Ward Location (N = 995, missing = 25)		
Medicine Wards	132 (13%)	71 (53.7)
Pediatric Wards	120 (12.1%)	94 (78.3)
Surgical Wards	209 (21.1%)	163 (78.0)
Gynecology Wards	194 (19.5%)	98 (50.5)
Adult ICU	27 (2.7%)	18 (66.7)
NICU	141 (14.5%)	107 (74.3%)
Pediatric ICU	12 (0.9%)	7 (77.8%)
Trauma	89 (8.9%)	75 (84.3)
Other Wards ¹	71 (7.1%)	10 (14.1)
Length of hospital stay		
Median (IQR)	6 (2–15)	2 (2–13.5)
Surgery Since Admission (n = 370)		
None	646 (63.3%)	370 (56.0%)
Major	343 (33.6%)	271 (41.0%)
Minor	27 (2.7%)	20 (3.0%)
Unknown	4 (0.39%)	1 (0.15%)
Total	1020	662 (64.9%)
Medical Device Use		
Central Venous Catheter (n = 11)	7 (0.7%)	4 (57.1%)
Urinary Catheter (n = 328)	180 (17.6%)	148 (82.2%)
Intubation (n = 58)	32 (3.1%)	26 (81.3%)
Medical Conditions		
Malaria (n = 9)	6 (0.6%)	3 (50%)
Tuberculosis (n = 36)	21 (2.1%)	15 (71.4%)
HIV (n = 69)	33 (3.2%)	26 (78.8%)
Sars-Cov2 test result (n = 376)	4	1 (25%)
Hospital Transfer (n = 114)	114 (11.2%)	80 (70.18%)
Hospitalized within 90 days	113 (11.1%)	94 (83.18%)
Culture Sample Obtained	74 (7.3%)	72 (97.3%)

HIV, human immunodeficiency virus; ICU, intensive care unit; SD, NICU, neonatal intensive care unit; SD, standard deviation, IQR, inter quartile range.

^aColumn percentage

^bRow percentage ¹Other Wards Include: Pediatric Oncology, Ear Nose Throat, Maxilo-facial Surgical Ward, Ophthalmology and Dermatology Wards.

Number of Antibiotics Receiving, Median (IQR)2 (1-2)Antibiotic Indication144 (22)Community acquired infection283 (43)Surgical prophylaxis181 (27)Medical prophylaxis31 (5)Other23 (3)Number of Antibiotics Prescribed Per Person Receiving an Antibiotic1316 (48)2311 (47)332 (5)≥43 (0.4)Treatment TypeEmpirical641 (97)Directed21 (3)No101 (15)Cutture Sample ObtainedYes561 (85)No101 (15)Cutture Sample ObtainedYes74 (11)Infectious Syndrome Treated8 (1)Cardiovascular4 (1)Respiratory96 (15)Gastrointestinal62 (9)Genito-urinary25 (4)Skin/soft tissue infection92 (14)Obstetric/gynecological86 (13)Sepsis/bacteremia99 (15)Musculoskeletal24 (4)Other infectious syndromes40 (6)	Characteristics	N (%)
Hospital acquired infection144 (22)Community acquired infection283 (43)Surgical prophylaxis181 (27)Medical prophylaxis31 (5)Other23 (3)Number of Antibiotics Prescribed Per Person Receiving an Antibiotic11316 (48)2311 (47)332 (5)≥43 (0.4)Treatment Type41 (97)Directed21 (3)Reason for Antibiotic Documented21 (3)Yes561 (85)No101 (15)Culture Sample Obtained58 (9)Head, ear, eye, nose, throat8 (1)Cardiovascular4 (1)Respiratory96 (15)Gastrointestinal62 (9)Genito-urinary25 (4)Skin/soft tissue infection68 (10)Surgical site infection92 (14)Obstetric/gynecological86 (13)Sepsis/bacteremia99 (15)Musculoskeletal24 (4)	Number of Antibiotics Receiving, Median (IQR)	2 (1-2)
Community acquired infection283 (43)Surgical prophylaxis181 (27)Medical prophylaxis31 (5)Other23 (3)Number of Antibiotics Prescribed Per Person Receiving an Antibiotic11316 (48)2311 (47)332 (5) ≥ 4 3 (0.4)Treatment Type1Empirical641 (97)Directed21 (3)Reason for Antibiotic Documented2Yes561 (85)No101 (15)Culture Sample Obtained58 (9)Head, ear, eye, nose, throat8 (1)Cardiovascular4 (1)Respiratory96 (15)Gastrointestinal62 (9)Gentro-urinary25 (4)Skin/soft tissue infection68 (10)Surgical site infection92 (14)Obstetric/gynecological86 (13)Sepsis/bacteremia99 (15)Musculoskeletal24 (4)	Antibiotic Indication	
Surgical prophylaxis181 (27)Medical prophylaxis31 (5)Other23 (3)Number of Antibiotics Prescribed Per Person Receiving an Antibiotic11316 (48)2311 (47)332 (5) ≥ 4 3 (0.4)Treatment Type1Empirical641 (97)Directed21 (3)Reason for Antibiotic Documented2Yes561 (85)No101 (15)Culture Sample Obtained101 (15)Culture Sample Obtained8 (1)Central nervous system58 (9)Head, ear, eye, nose, throat8 (1)Cardiovascular4 (1)Respiratory96 (15)Gastrointestinal62 (9)Gentio-urinary25 (4)Skin/soft tissue infection68 (10)Surgical site infection92 (14)Obstetric/gynecological86 (13)Sepsis/bacteremia99 (15)Musculoskeletal24 (4)	Hospital acquired infection	144 (22)
Medical prophylaxis $31 (5)$ Other $23 (3)$ Number of Antibiotics Prescribed Per Person Receiving an Antibiotic1 $316 (48)$ 2 $311 (47)$ 3 $32 (5)$ ≥ 4 $3 (0.4)$ Treatment TypeEmpirical $641 (97)$ Directed $21 (3)$ Reason for Antibiotic DocumentedYes $561 (85)$ No $101 (15)$ Culture Sample ObtainedYes $74 (11)$ Infectious Syndrome TreatedCentral nervous system $58 (9)$ Head, ear, eye, nose, throat $8 (1)$ Cardiovascular $4 (1)$ Respiratory $96 (15)$ Gastrointestinal $62 (9)$ Genito-urinary $25 (4)$ Skin/soft tissue infection $92 (14)$ Obstetric/gynecological $86 (13)$ Sepsis/bacteremia $99 (15)$ Musculoskeletal $24 (4)$	Community acquired infection	283 (43)
Other23 (3)Number of Antibiotics Prescribed Per Person Receiving an Antibiotic1316 (48)2311 (47)332 (5) ≥ 4 3 (0.4)Treatment Type641 (97)Empirical641 (97)Directed21 (3)Reason for Antibiotic Documented21 (3)Ves561 (85)No101 (15)Culture Sample Obtained2Yes74 (11)Infectious Syndrome Treated8 (1)Central nervous system58 (9)Head, ear, eye, nose, throat8 (1)Cardiovascular4 (1)Respiratory96 (15)Gastrointestinal62 (9)Genito-urinary25 (4)Skin/soft tissue infection68 (10)Surgical site infection92 (14)Obstetric/gynecological86 (13)Sepsis/bacteremia99 (15)Musculoskeletal24 (4)	Surgical prophylaxis	181 (27)
Number of Antibiotics Prescribed Per Person Receiving an Antibiotic1316 (48)2311 (47)332 (5)≥43 (0.4)Treatment TypeEmpirical641 (97)Directed21 (3)Reason for Antibiotic DocumentedYes561 (85)No101 (15)Culture Sample ObtainedYes74 (11)Infectious Syndrome TreatedCentral nervous system58 (9)Head, ear, eye, nose, throat8 (1)Cardiovascular4 (1)Respiratory96 (15)Gastrointestinal62 (9)Genito-urinary25 (4)Skin/soft tissue infection92 (14)Obstetric/gynecological86 (13)Sepsis/bacteremia99 (15)Musculoskeletal24 (4)	Medical prophylaxis	31 (5)
1316 (48)2311 (47)332 (5)≥43 (0.4)Treatment Type $(41, 97)$ Empirical $641 (97)$ Directed21 (3)Reason for Antibiotic Documented $(41, 97)$ Yes $561 (85)$ No101 (15)Culture Sample Obtained $(41, 11)$ Infectious Syndrome Treated (41) Central nervous system $58 (9)$ Head, ear, eye, nose, throat $8 (1)$ Cardiovascular $4 (1)$ Respiratory $96 (15)$ Gastrointestinal $62 (9)$ Genito-urinary $25 (4)$ Skin/soft tissue infection $92 (14)$ Obstetric/gynecological $86 (13)$ Sepsis/bacteremia $99 (15)$ Musculoskeletal $24 (4)$	Other	23 (3)
2 $311 (47)$ 3 $32 (5)$ ≥4 $3 (0.4)$ Treatment TypeEmpirical $641 (97)$ Directed $21 (3)$ Reason for Antibiotic DocumentedYes $561 (85)$ No $101 (15)$ Culture Sample ObtainedYes $74 (11)$ Infectious Syndrome Treated $8 (1)$ Central nervous system $58 (9)$ Head, ear, eye, nose, throat $8 (1)$ Cardiovascular $4 (1)$ Respiratory $96 (15)$ Gastrointestinal $62 (9)$ Genito-urinary $25 (4)$ Skin/soft tissue infection $92 (14)$ Obstetric/gynecological $86 (13)$ Sepsis/bacteremia $99 (15)$ Musculoskeletal $24 (4)$	Number of Antibiotics Prescribed Per Person Receiving an	Antibiotic
Image: second systemSecond system332 (5)≥43 (0.4)641 (97)641 (97)21 (3)74 (13)561 (85)74 (11)74 (11)58 (9)58 (9)8 (1)62 (9)62 (9)68 (10)58 (10)58 (10)68 (10)68 (10)68 (10)68 (10)92 (14)99 (15)99 (15)99 (15)99 (15)99 (15)99 (15)99 (15)99 (15)99 (15)24 (4)	1	316 (48)
≥43 (0.4)Treatment TypeEmpirical641 (97)Directed21 (3)Reason for Antibiotic DocumentedYes561 (85)No101 (15)Culture Sample ObtainedYes74 (11)Infectious Syndrome TreatedCentral nervous system58 (9)Head, ear, eye, nose, throat8 (1)Cardiovascular4 (1)Respiratory96 (15)Gastrointestinal62 (9)Genito-urinary25 (4)Skin/soft tissue infection68 (10)Surgical site infection92 (14)Obstetric/gynecological86 (13)Sepsis/bacteremia99 (15)Musculoskeletal24 (4)	2	311 (47)
Treatment TypeEmpirical641 (97)Directed21 (3)Reason for Antibiotic Documented21 (3)Yes561 (85)No101 (15)Culture Sample Obtained101 (15)Yes74 (11)Infectious Syndrome Treated21 (3)Central nervous system58 (9)Head, ear, eye, nose, throat8 (1)Cardiovascular4 (1)Respiratory96 (15)Gastrointestinal62 (9)Genito-urinary25 (4)Skin/soft tissue infection68 (10)Surgical site infection92 (14)Obstetric/gynecological86 (13)Sepsis/bacteremia99 (15)Musculoskeletal24 (4)	3	32 (5)
Empirical641 (97)Directed21 (3)Reason for Antibiotic DocumentedYes561 (85)No101 (15)Culture Sample ObtainedYes74 (11)Infectious Syndrome TreatedCentral nervous system58 (9)Head, ear, eye, nose, throat8 (1)Cardiovascular4 (1)Respiratory96 (15)Gastrointestinal62 (9)Genito-urinary25 (4)Skin/soft tissue infection68 (10)Surgical site infection99 (15)Musculoskeletal24 (4)	≥4	3 (0.4)
Directed21 (3)Reason for Antibiotic DocumentedYes561 (85)No101 (15)Culture Sample Obtained74 (11)Infectious Syndrome Treated74 (11)Central nervous system58 (9)Head, ear, eye, nose, throat8 (1)Cardiovascular4 (1)Respiratory96 (15)Gastrointestinal62 (9)Genito-urinary25 (4)Skin/soft tissue infection68 (10)Surgical site infection92 (14)Obstetric/gynecological86 (13)Sepsis/bacteremia99 (15)Musculoskeletal24 (4)	Treatment Type	
Reason for Antibiotic DocumentedYes561 (85)No101 (15)Culture Sample Obtained101 (15)Yes74 (11)Infectious Syndrome Treated101Central nervous system58 (9)Head, ear, eye, nose, throat8 (1)Cardiovascular4 (1)Respiratory96 (15)Gastrointestinal62 (9)Genito-urinary25 (4)Skin/soft tissue infection68 (10)Surgical site infection92 (14)Obstetric/gynecological86 (13)Sepsis/bacteremia99 (15)Musculoskeletal24 (4)	Empirical	641 (97)
Yes561 (85)No101 (15)Culture Sample Obtained74 (11)Infectious Syndrome Treated74 (11)Infectious Syndrome Treated8 (9)Head, ear, eye, nose, throat8 (1)Cardiovascular4 (1)Respiratory96 (15)Gastrointestinal62 (9)Genito-urinary25 (4)Skin/soft tissue infection68 (10)Surgical site infection92 (14)Obstetric/gynecological86 (13)Sepsis/bacteremia99 (15)Musculoskeletal24 (4)	Directed	21 (3)
No101 (15)Culture Sample Obtained74 (11)Infectious Syndrome Treated74 (11)Infectious Syndrome Treated8 (1)Central nervous system58 (9)Head, ear, eye, nose, throat8 (1)Cardiovascular4 (1)Respiratory96 (15)Gastrointestinal62 (9)Genito-urinary25 (4)Skin/soft tissue infection68 (10)Surgical site infection92 (14)Obstetric/gynecological86 (13)Sepsis/bacteremia99 (15)Musculoskeletal24 (4)	Reason for Antibiotic Documented	
Culture Sample ObtainedYes74 (11)Infectious Syndrome TreatedCentral nervous system58 (9)Head, ear, eye, nose, throat8 (1)Cardiovascular4 (1)Respiratory96 (15)Gastrointestinal62 (9)Genito-urinary25 (4)Skin/soft tissue infection68 (10)Surgical site infection92 (14)Obstetric/gynecological86 (13)Sepsis/bacteremia99 (15)Musculoskeletal24 (4)	Yes	561 (85)
Yes74 (11)Infectious Syndrome TreatedCentral nervous system58 (9)Head, ear, eye, nose, throat8 (1)Cardiovascular4 (1)Respiratory96 (15)Gastrointestinal62 (9)Genito-urinary25 (4)Skin/soft tissue infection68 (10)Surgical site infection92 (14)Obstetric/gynecological86 (13)Sepsis/bacteremia99 (15)Musculoskeletal24 (4)	No	101 (15)
Infectious Syndrome TreatedCentral nervous system58 (9)Head, ear, eye, nose, throat8 (1)Cardiovascular4 (1)Respiratory96 (15)Gastrointestinal62 (9)Genito-urinary25 (4)Skin/soft tissue infection68 (10)Surgical site infection92 (14)Obstetric/gynecological86 (13)Sepsis/bacteremia99 (15)Musculoskeletal24 (4)	Culture Sample Obtained	
Central nervous system58 (9)Head, ear, eye, nose, throat8 (1)Cardiovascular4 (1)Respiratory96 (15)Gastrointestinal62 (9)Genito-urinary25 (4)Skin/soft tissue infection68 (10)Surgical site infection92 (14)Obstetric/gynecological86 (13)Sepsis/bacteremia99 (15)Musculoskeletal24 (4)	Yes	74 (11)
Head, ear, eye, nose, throat8 (1)Cardiovascular4 (1)Respiratory96 (15)Gastrointestinal62 (9)Genito-urinary25 (4)Skin/soft tissue infection68 (10)Surgical site infection92 (14)Obstetric/gynecological86 (13)Sepsis/bacteremia99 (15)Musculoskeletal24 (4)	Infectious Syndrome Treated	
Cardiovascular4 (1)Respiratory96 (15)Gastrointestinal62 (9)Genito-urinary25 (4)Skin/soft tissue infection68 (10)Surgical site infection92 (14)Obstetric/gynecological86 (13)Sepsis/bacteremia99 (15)Musculoskeletal24 (4)	Central nervous system	58 (9)
Respiratory96 (15)Gastrointestinal62 (9)Genito-urinary25 (4)Skin/soft tissue infection68 (10)Surgical site infection92 (14)Obstetric/gynecological86 (13)Sepsis/bacteremia99 (15)Musculoskeletal24 (4)	Head, ear, eye, nose, throat	8 (1)
Gastrointestinal62 (9)Genito-urinary25 (4)Skin/soft tissue infection68 (10)Surgical site infection92 (14)Obstetric/gynecological86 (13)Sepsis/bacteremia99 (15)Musculoskeletal24 (4)	Cardiovascular	4 (1)
Genito-urinary25 (4)Skin/soft tissue infection68 (10)Surgical site infection92 (14)Obstetric/gynecological86 (13)Sepsis/bacteremia99 (15)Musculoskeletal24 (4)	Respiratory	96 (15)
Skin/soft tissue infection68 (10)Surgical site infection92 (14)Obstetric/gynecological86 (13)Sepsis/bacteremia99 (15)Musculoskeletal24 (4)	Gastrointestinal	62 (9)
Surgical site infection92 (14)Obstetric/gynecological86 (13)Sepsis/bacteremia99 (15)Musculoskeletal24 (4)	Genito-urinary	25 (4)
Obstetric/gynecological86 (13)Sepsis/bacteremia99 (15)Musculoskeletal24 (4)	Skin/soft tissue infection	68 (10)
Sepsis/bacteremia99 (15)Musculoskeletal24 (4)	Surgical site infection	92 (14)
Musculoskeletal 24 (4)	Obstetric/gynecological	86 (13)
	Sepsis/bacteremia	99 (15)
Other infectious syndromes 40 (6)	Musculoskeletal	24 (4)
	Other infectious syndromes	40 (6)

Percentages have been rounded to the nearest whole numbers'.

Gastrointestinal: includes diarrheal illness and intra-abdominal infections.

Genito-urinary: includes lower urinary tract infection, upper urinary tract infection,

prostatitis, and orchitis. Excluded asymptomatic bacteriuria, which is not recommended to be treated with antibiotics except in specific clinical scenarios.

Sepsis/bacteremia: includes bacteremia, clinical sepsis, and systemic inflammatory response syndrome.

Other: includes sexually transmitted infections, febrile neutropenia, and other undefined infections.

Skin/soft tissue infection includes cellulitis, wound, deep soft tissue infection (not involving bone), unrelated to recent surgery.

Musculoskeletal infections: includes osteomyelitis, septic arthritis, not related to recent surgery.

Surgical site infection includes skin/soft tissue or bone/joint infection, related to surgery.

for antibiotic use was documented in most cases (85%), few patients had samples collected for microbiological analysis (11%), and hence almost all antibiotic use was empiric (96%). Regarding clinical syndromes, a variety of infectious syndromes were reported as indications for antibiotics as listed in Table 2. The most common infectious syndromes reported were sepsis/ bacteremia (15%), respiratory infections (15%), surgical site infection (14%), and OB/GYN-related infections (13%).

Antibiotics use by indication and by hospital ward

Among the 662 patients receiving antibiotics, a total of 1044 antibiotics were being prescribed on the day of survey. Cephalosporins (42%) followed by penicillins (16%) were the most prescribed antibiotic classes. The most frequently prescribed specific antibiotics were ceftriaxone (34%), ampicillin (15%) and metronidazole (14%) (Figure 1). Frequency of prescribed antibiotics among hospitalized patients with more than 10 uses (N = 1044). It is worth noting that 29 patients, mostly children (n = 22) received meropenem. The most common antibiotics by treatment indication are shown in Table 3.

Ceftriaxone was prescribed for 53% of patients receiving antibiotics for surgical prophylaxis and for 31% of people receiving antibiotics for a community-acquired infection. A total of 492 antibiotics were used for community-acquired infections followed by 243 for hospital-acquired and 217 for surgical prophylaxis. From all 1011(33 missing) antibiotics reported from the study wards, 23%, 20%, and 15% were reported from surgical ward, NICU, and pediatric ward, respectively. Ceftriaxone and metronidazole were the most frequently used antibiotics in surgical wards while ampicillin and aminoglycosides use were high in the NICU (Tables 3 and 4).

Discussion

Our antibiotic use PPS performed at two large referral hospitals in Addis Ababa found a very high rate of antibiotic use, with nearly two-thirds of all hospitalized patients receiving ≥ 1 antibiotic. This concerning high rate of antibiotic use correlates with the results of a recent multicenter antimicrobial use study conducted in Ethiopia in which 63% of patients were receiving antibiotics.¹⁶ Similar rates of antibiotic use have been found in other prevalence studies in sub-Saharan Africa (60% in Nigeria, 74% in Uganda), and in the global PPS data for Africa in 2015.¹⁰⁻¹³ However, rates are much higher than antibiotic use rates in high-income countries including the United States where hospital antibiotic use rates are \sim 50% in national surveys.²⁴ Most antibiotics were prescribed empirically, with only about 1 in 10 patients having samples collected for microbiological cultures. This high rate of empiric prescribing and low microbiological testing aligns with PPS studies from other Sub Saharan Africa (SSA) countries, including Ghana, Tanzania, Kenya, and Nigeria.²⁵⁻²⁸ Our high rate of antibiotic use along with lack of microbiological sample collection and confirmation of infection highlight the urgent need to enhance microbiology laboratory capacity to aid in targeted and appropriate antibiotic use.²⁹

Despite these alarming reports, the implementation of antimicrobial stewardship programs is only in its early stages across most low and middle-income countries.³⁰ Our findings of high rates of empiric antibiotic use in hospitals, in addition to the rising rates of AMR in SSA,^{31–33} highlight the urgency for prioritizing and implementing stewardship programs.

Community-acquired infections (43%) and surgical prophylaxis (22%) were the most frequently identified indication for antibiotic prescription, with clinical sepsis and respiratory infections being the most common clinical syndromes treated with antibiotics. These findings are similar to those from a recent multicentred antibiotic PPS in Uganda in which the most common indications were community-acquired infection (42%) and

Table 3. Frequency of antibiotic prescribing among hospitalized patients by treatment indication

Antibiotic Classes and/or Individual Drugs	Community-acquired infection $N = 492 (47)^*$	Hospital-acquired infection N = 243 (23)	Medical prophylaxis N = 46 (4%)	Surgical prophylaxis N = 217 (24)	Others N = 42 (4)	Total N = 1040 (100)
Penicillin	80 (16)	18 (7)	9 (20)	58 (27)	6 (14)	171 (16)
Amoxicillin/clavulanate	-	2	-	2	2	6
Amoxicillin	1	-	3	-	-	4
Ampicillin	76	16	6	56	4	158
Cloxacillin	3	3 -		-	-	3
Cephalosporin	197 (40)	79 (33)	20 (43)	120 (55)	17 (40)	433 (42)
1st Generation (Cephalexin)	1	-	-	-	2	3
2 nd Generation (Cefuroxime)	-	1	-	-	-	1
3 rd Generation						
– Cefixime	2	2	1	1	-	6
– Cefotaxime	25	2	2	-	1	30
– Ceftazidime	16	17	1	-	4	38
– Ceftriaxone	153	57	16	119	10	355
Carbapenem – Meropenem	6 (1)	24 (10)	0	0	0	30 (3)
Glycopeptides – Vancomycin	47 (10)	38 (16)	3 (7)	3 (1)	7 (17)	98 (9)
Macrolides	10 (2)	4 (2)	1 (2)	1 (1)	0	16 (2)
Clarithromycin	1	1	-	1	-	3
Azithromycin	9	2	1	-	-	12
Erythromycin	-	1	-	-	-	1
Tetracyclines	2 (0.4)	1 (0.4)	0	0	0	3 (0.3)
Doxycycline	2	-	-	-	-	2
Tetracycline	-	1	-	-	-	1
Fluoroquinolone – Ciprofloxacin	7(1)	24 (10)	0	1 (1)	1 (2)	33
Aminoglycoside – Gentamycin	47 (10)	5 (2)	4 (9)	2 (1)	3 (7)	61 (6)
Nitroimidazole – Metronidazole	73 (15)	30 (12)	4 (9)	32 (15)	6 (14)	145 (14)
Sulfonamide – Trimethoprim/sulfamethoxazole	9 (2)	2 (1)	4 (9)	0	0	15 (1)
Other	14 (3)	18 (7)	1 (1)	-	2 (5)	35

Percentages have been rounded to the nearest whole number.

* () indicates percentage. ^ Other Indications Include; Fulminant hepatitis, Acute cholecystitis, Neutropenic Fever (2), Puerperal sepsis (2), Pyomyositis+ abscess, Sepsis of wound focus, Septic shock of GI focus, UTI, Oronasal fistula.




Figure 1. Frequency of most commonly prescribed antibiotics among inpatients at two hospitals in Addis Ababa, Ethiopia, December 2020-January 2021 (N = 1020). Only antibiotics prescribed >10 times were included in the figure.

Table 4. Frequency of antibiotic prescribing among hospitalized patients by hospital ward

Antibiotics	Adult ICU N = 34 (3)	Gynecology N = 130 (13)	Medical ward N = 121 (2)	NICU N = 201 (20)	Pediatric Ward N = 153 (15)	Pediatric ICU N = 12(1)	Surgical Wards N = 230 (23)	Trauma N = 117 (12)	Other wards N = 13 (1)	Total N = 1011**
Penicillins	0	78 (60)	3 (2)	70(20)	14 (9)	0	3 (1)	0	1 (8)	169
Amoxicillin/clavulanate	-	4	1	-	-		-	-	1	6
Amoxicillin	-	58	-	-	1		-	-	-	59
Ampicillin	-	16	2	70	12	0	1	-	-	101
Cloxacillin	-	-	-	-	1		2	-	-	3
Cephalosporins	12 (35)	19 (15)	49 (40)	22 (11)	79 (52)	3 (25)	155 (67)	74 (63)	7 (54)	420
1st Generation (Cephalexin)		1	-		1				-	2
2 nd Generation (Cefuroxime)	-		-	1					-	1
3 rd Generation										
– Cefixime	-	-	1	-	4		-	1	-	6
– Cefotaxime	-	-	1	19	7	1	-	1	-	29
– Ceftazidime	3	1	18	1	6	1	6	2	-	38
– Ceftriaxone	9	17	29	1	61	1	149	70	7	344
Carbapenems	2 (6)	0	1 (1)	18 (9)	2 (1)	2 (17)	4 (2)	0	0	29
Meropenem	2	-	1	18	2	2	4	-	-	29
Glycopeptides	10 (29)	1 (1)	26 (21)	17 (8)	26 (17)	4 (33)	7 (3)	3 (3)	0	94
Vancomycin	10	1	26	17	26	4	7	3	-	94
Macrolides	0	2 (2)	5 (4)	1(1)	5 (3)	0	0	1 (1)	0	14
Clarithromycin	-	-	1	-	-		-	-	-	1
Azithromycin	-	2	4	1	5		-	-	-	12
Erythromycin	-	-	-	-	-		-	1	-	1
Tetracyclines	0	1 (1)	1 (1)	1(1)	0	0	1 (0.4)	0	0	4
Doxycycline	-	1	1	-	-		1	-	-	3
Tetracycline Hydrochloride	-	-	-	1	-		-	-	-	1
Fluoroquinolones	0	0	4 (3)	16 (8)	1 (1)	0	8 (3)	1 (1)	0	30
Ciprofloxacin	-	-	4	16	1		8	1	-	30
Aminoglycosides	0	7 (5)	3 (2)	40 (19)	8 (5)	1 (8)	0	1 (1)	0	60
Gentamicin	-	7	3	40	8	1	-	1	-	60
Nitroimidazole	8 (24)	16 (12)	14 (12)	1 (1)	9 (6)	1 (8)	50 (22)	37 (31)	4 (31)	140
Metronidazole	8	16	14	1	9	1	50	37	4	140
Sulfonamides	-	-	11(9)	-	4 (3)	0	0	0	0	15
Trimethoprim/ sulfamethoxazole	0	0	11	0	4	0	0	0	0	15
Other	2 (6)	6 (5)	4 (3)	15 (7)	5 (3)	1(8)	2 (1)	0	1 (8)	36

Percentages have been rounded to the nearest whole number.

**Missing data for specific antibiotics for 33 patients.

* () indicates percentage.

surgical prophylaxis (21%).³⁴ Similarly, in Ghana, communityacquired infecton (37%) and surgical prophylaxis (26%) were also the most common reason for antibiotic prescription.²⁶ In Tanzania, 42% of antibiotic prescriptions were indicated for community-acquired infections.^{11–13,16} These findings highlight the need for enhanced diagnostic including microbiology methods and developing protocols to standardize the use of antibiotics for surgical prophylaxis.

Ceftriaxon and metronidazole constituted 35% of the antibiotics prescribed for surgical prophylaxis. Ceftriaxon is used as empiric therapy throughout SSA despite recent studies reporting 57%–60% of ceftriaxone resistance in Ethiopia.^{35,36} High number of antibiotics were prescribed in surgical wards, likely related to the high prevalence of surgical site infections.³⁷ Hospital-acquired infection was the second common indication for antibiotic prescription in our study. Strengthening infection prevention efforts in hospitals is crucial, as de-escalation to targeted therapy is hindered by the lack of microbiology data.

Study limitations include being conducted at tertiary referral hospitals which may not be representative of general or primary hospitals. Our PPS captured only the antibiotics patients were receiving at the time of data collection and does not reflect additional antibiotics they may have received during hospitalization. Therefore, our estimates could be an underrepresentation of overall antibiotic use. Due to the cross-sectional nature of the PPS, we were unable to determine the length of antibiotic duration or de-escalation strategies, both important metrics for antimicrobial stewardship. Future studies evaluating the proportion of appropriate versus inappropriate antibiotic use are needed to identify targeted opportunities for antibiotic stewardship interventions.

Conclusions

Despite global efforts to improve antimicrobial stewardship in the context of rising AMR-associated infections and deaths, we found high rates of empiric antibiotic use in Ethiopia and low rates of microbiological sampling for cultures. Antibiotic surveys serve as an important assessment tool and results can be used by national programs and hospitals to enhance antibiotic stewardship activities and develop optimized strategies to curtail excessive antibiotic use that are tailored to the local context.

Supplementary material. The supplementary material for this article can be found at https://doi.org/10.1017/ash.2024.432.

Acknowledgments. This research was supported by the Emory Global Health Institute. We would like to express our gratitude to the dedicated data collectors who invested their time and efforts in conducting the PPS at St. Paul's Hospital Millennium Medical College (SPMMC) and ALERT Specialized Hospital: We would also like to acknowledge the unwavering support and cooperation of the staff and faculty at the All-Africa Leprosy, Tuberculosis and Rehabilitation and Training Center (ALERT) Hospital and SPHMMC, who provided the necessary resources and facilities for our research.

All the authors (Kassa Haile Merga, Edlawit Mesfin Getachew, Ayako Wendy Fujita, Mahlet Abayneh Jesse T. Jacob, Solomon Ali, Hayat Oumer, Ahmed Babiker, Liya Sisay, Tsegaye Hailu, Jemal Mohammed1, Bethelhem Solomon, Paulina A. Rebolledo, Alemseged Abdissa, Russell R. Kempker) declare that they have no conflicts of interest to disclose for the past three years.

References

- Bryan-Wilson J. No time to wait, securing the future from drug-resistant infections, report to the secretary-general of the United Nations. *Artforum Int* 2016;54(10):113–114.
- Sartorius B, Gray AP, Davis Weaver N, *et al.* The burden of bacterial antimicrobial resistance in the WHO African region in 2019: a crosscountry systematic analysis. *Lancet Glob Health.* Published online December 2023. doi:10.1016/s²²14-109x(23)00539-9
- 3. Murray CJ, Ikuta KS, Sharara F, *et al.* Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *Lancet* 2022;399(10325):629–655.
- European Public Health Alliance (EPHA). An overview of antimicrobial resistance the health burden, science, surveillance, policy developments and areas of future action. 2022;(May). https://epha.org/wp-content/uploads/ 2022/05/amr-overview-2022-epha.pdf
- Browne AJ, Chipeta MG, Haines-Woodhouse G, et al. Global antibiotic consumption and usage in humans, 2000–18: a spatial modelling study. Lancet Planet Health 2021;5(12):e893–e904. doi: 10.1016/S2542-5196(21)00280-1
- OMS. Global action plan on antimicrobial resistance. World Health Organization. Published online 2017:1-28.
- World Health Organization. WHO Methodology for Point Prevalence Survey on Antibiotic Use in Hospitals. Published online 2018.

- Versporten A, Drapier N, Zarb P, et al. I D W E E K 2 0 1 5 POSTER ABSTRACTS 147. The Global Point Prevalence Survey of Antimicrobial Consumption and Resistance (Global-PPS): A Worldwide Antimicrobial Web-Based Point Prevalence Survey. Published online 2015. doi: 10.1093/ ofid/ofv133
- 9. Www.global-pps.com. Global Point Prevalence What Is the Global Point Prevalence, Scientific Publications.
- Versporten A, Zarb P, Caniaux I, *et al.* Antimicrobial consumption and resistance in adult hospital inpatients in 53 countries: results of an internetbased global point prevalence survey. *Lancet Glob Health* 2018;6(6): e619–e629.
- 11. Fowotade A, Fasuyi T, Aigbovo O, *et al.* Point prevalence survey of antimicrobial prescribing in a nigerian hospital: findings and implications on antimicrobial resistance. *West Afr J Med* 2020;37(3):216–220.
- Horumpende PG, Mshana SE, Mouw EF, Mmbaga BT, Chilongola JO, De Mast Q. Point prevalence survey of antimicrobial use in three hospitals in North-Eastern Tanzania. *Antimicrob Resist Infect Control* 2020;9(1):1–6.
- Kiggundu R, Wittenauer R, Waswa JP, *et al.* Point Prevalence Survey of Antibiotic Use across 13 Hospitals in Uganda. *Antibiotics.* 2022;11(2):1–21. doi: 10.3390/antibiotics11020199
- Omulo S, Oluka M, Achieng L, *et al.* Point-prevalence survey of antibiotic use at three public referral hospitals in Kenya. *PLoS One* 2022;17(6): e0270048.
- Berhe DF, Beyene GT, Seyoum B, et al. Prevalence of antimicrobial resistance and its clinical implications in Ethiopia: a systematic review. Antimicrob Resist Infect Control 2021;10(1):1–14.
- Fentie AM, Degefaw Y, Asfaw G, *et al.* Multicentre point-prevalence survey of antibiotic use and healthcare-associated infections in Ethiopian hospitals. *BMJ Open* 2022;12(2):1–10.
- Fujita AW, Werner K, Jacob JT, et al. Antimicrobial resistance through the lens of one health in Ethiopia: a review of the literature among humans, animals, and the environment. Int J Infect Dis 2022;119:120–129.
- Gemeda BA, Assefa A, Jaleta MB, Amenu K, Wieland B. Antimicrobial resistance in Ethiopia: a systematic review and meta-analysis of prevalence in foods, food handlers, animals, and the environment. *One Health* 2021;13:100286.
- Melaku T, Gashaw M, Chelkeba L, *et al*. Evaluation of adult outpatient antibiotics use at jimma medical center (with defined daily doses for usage metrics). *Infect Drug Resist* 2021;14:1649–1658.
- 20. AMR Prevention and Containment Strategic Plan: 2021-2025.
- 21. For Point Prevalence Survey on Antibiotic Use in Hospitals WHO Methodology.
- Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform 2019;95:103208.
- World Health Organization. WHO Methodology for Point Prevalence Survey on Antibiotic Use in Hospitals. Published online 2018.
- Magill SS, O'Leary E, Ray SM, et al. Antimicrobial Use in US Hospitals: Comparison of Results from Emerging Infections Program Prevalence Surveys, 2015 and 2011. Clin Infect Dis 2021;72(10):1784–1792.
- 25. Horumpende PG, Mshana SE, Mouw EF, Mmbaga BT, Chilongola JO, De Mast Q. Point prevalence survey of antimicrobial use in three hospitals in North-Eastern Tanzania. *Antimicrob Resist Infect Control* 2020;9(1):1-6.
- 26. Labi AK, Obeng-Nkrumah N, Dayie NTKD, *et al.* Antimicrobial use in hospitalized patients: A multicentre point prevalence survey across seven hospitals in Ghana. *JAC Antimicrob Resist* 2021;3(3):dlab087.
- 27. Fowotade A, Fasuyi T, Aigbovo O, *et al.* Point prevalence survey of antimicrobial prescribing in a Nigerian hospital: findings and implications on antimicrobial resistance. *West Afr J Med* 2020;37(3):216–220.
- Omulo S, Oluka M, Achieng L, et al. Point-prevalence survey of antibiotic use at three public referral hospitals in Kenya. PLoS One 2022;17(6): e0270048.
- Ombelet S, Ronat JB, Walsh T, et al. Clinical bacteriology in low-resource settings: today's solutions. Lancet Infect Dis. 2018;18(8):e248–e258.

- Elton L, Thomason MJ, Tembo J, et al. Antimicrobial resistance preparedness in sub-Saharan African countries. Antimicrob Resist Infect Control. 2020;9(1):1–11.
- Moyo P, Moyo E, Mangoya D, *et al.* Prevention of antimicrobial resistance in sub-Saharan Africa: What has worked? What still needs to be done? *J Infect Public Health.* 2023;16(4):632–639.
- 32. Ndihokubwayo JB, Yahaya AA, Desta AT, et al. Antimicrobial Resistance in the African Region: Issues, Challenges and Actions Proposed. http://www.who.int/bulletin/
- 33. Moyo P, Moyo E, Mangoya D, *et al.* Prevention of antimicrobial resistance in sub-Saharan Africa: What has worked? What still needs to be done? *J Infect Public Health.* 2023;16(4):632–639.
- 34. Kiggundu R, Wittenauer R, Waswa JP, et al. Point prevalence survey of antibiotic use across 13 hospitals in Uganda. Antibiotics 2022;11(2): 1–21.
- 35. Lee H, Jung D, Yeom JS, *et al.* Evaluation of ceftriaxone utilization at multicenter study. *Korean J Intern Med* 2009;24(4):374–380.
- Muhammed OS, Nasir BB. Drug use evaluation of ceftriaxone in Ras-Desta Memorial General Hospital, Ethiopia. Drug Healthc Patient Saf 2020;12:161–168.
- 37. Kefale B, Tegegne GT, Degu A, Molla M, Kefale Y. Surgical site infections and prophylaxis antibiotic use in the surgical ward of public hospital in western ethiopia: A hospital-based retrospective cross-sectional study. *Infect Drug Resist* 2020;13:3627–3635.